OncoMatch/Clinical Trials/NCT03287271

ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK

Is NCT03287271 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including VS-6063 and Paclitaxel for ovarian cancer.

Phase 1/2RecruitingMichael McHaleNCT03287271Data as of May 2026

Treatment: VS-6063 · Paclitaxel · Carboplatin — The purpose of the study is to investigate the combination VS-6063, carboplatin, and paclitaxel. in the treatment of patients with ovarian cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Ovarian Cancer

Prior therapy

Max 2 prior lines

Min 1 prior line

Must have received: platinum-based chemotherapy (carboplatin, cisplatin) — primary disease

Must have had one prior platinum-based chemotherapeutic regimen for management of primary disease containing carboplatin, cisplatin, or another organoplatinum compound.

Cannot have received: kinase inhibitor

History of treatment with known kinase inhibiting agents.

Lab requirements

Blood counts

adequate bone marrow function

Kidney function

adequate renal function

Liver function

adequate hepatic function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

University of California San Diego · San Diego, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify